3/2
07:00 am
nvcr
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
Low
Report
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
2/27
10:34 pm
nvcr
NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/27
04:30 pm
nvcr
Novocure to Participate in 2026 Leerink Global Healthcare Conference
Low
Report
Novocure to Participate in 2026 Leerink Global Healthcare Conference
2/26
01:58 pm
nvcr
NovoCure (NVCR) had its price target raised by HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.
Medium
Report
NovoCure (NVCR) had its price target raised by HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.
2/26
07:51 am
nvcr
NovoCure: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
NovoCure: Q4 Earnings Snapshot [Yahoo! Finance]
2/26
07:10 am
nvcr
NovoCure GAAP EPS of -$0.22 beats by $0.19, revenue of $174.35M beats by $0.99M [Seeking Alpha]
Medium
Report
NovoCure GAAP EPS of -$0.22 beats by $0.19, revenue of $174.35M beats by $0.99M [Seeking Alpha]
2/26
07:00 am
nvcr
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Medium
Report
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
2/24
07:00 am
nvcr
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
Medium
Report
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
2/12
07:17 am
nvcr
NovoCure (NASDAQ:NVCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
NovoCure (NASDAQ:NVCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/11
05:54 pm
nvcr
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
High
Report
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
1/15
09:19 am
nvcr
NovoCure (NASDAQ:NVCR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Low
Report
NovoCure (NASDAQ:NVCR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
1/13
02:54 pm
nvcr
Why NovoCure Is Failing To Disrupt NSCLC [Seeking Alpha]
Low
Report
Why NovoCure Is Failing To Disrupt NSCLC [Seeking Alpha]
1/13
08:03 am
nvcr
NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at HC Wainwright from $42.00 to $39.00. They now have a "buy" rating on the stock.
Low
Report
NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at HC Wainwright from $42.00 to $39.00. They now have a "buy" rating on the stock.
1/12
07:00 am
nvcr
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
Low
Report
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
1/5
12:01 pm
nvcr
NovoCure (NASDAQ:NVCR) was given a new $20.00 price target on by analysts at Evercore ISI.
Low
Report
NovoCure (NASDAQ:NVCR) was given a new $20.00 price target on by analysts at Evercore ISI.
12/22
07:00 am
nvcr
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference